Amarin Corp PLC (AMRN) News

Denisk, Kiwi, thanks. To answer Denisk, I have had this position for 2 years with a cost basis in the 80's. It is in my dividend portfolio for income. Seems a reaction to the election - they are a REIT that caters to the MJ market. Revenue might be light comparatively but over a 50% net profit margin. Waiting for 3Q earnings that was supposed to be released today after market, but company website indicates ER tomorrow. Kiwi, yet ARDX and RZLT did well today. I have not reduced any of those positions. Good luck to us all.

Kube, generally no. Scripts normally aren't written with an indication on them.

This is one of the big weaknesses of our healthcare system. It's difficult to point the finger at any one party. Docs just prescribe what they prescribe. Pharmacies fill whatever the doctor prescribes. Insurers may or may not cover, and have lists of generic "equivalents". Pharmacists have no way of knowing an indication the script is for, or what a particular drug is indicated for (relative to its patented use). Manufacturers just claim ignorance (unless they get caught marketing incorrectly 😜)

So that is exactly why Amarin (and we) have been screwed by the system. It should all be 100% automated, starting in the docs office. Scripts should not be written or filled for a drug that is not patented for use with a specific indication. But the current system just doesn't catch it.

And even if Hikma DID market correctly, the problem would still persist. We just happened to get lucky (we hope) that Hikma DID fuck up.

looks very expensive considering revenue level. High PE ration of 21. depending of your share cost price, you might want to lighten your position. IMO just a thought

Yeah but you also have RZLT don't U ...up around 500% this year . And your ARDX may benefit from a Trump win .
AMRN isn't a Trump play ...unless poster Capt can identify a way it is
IIPR ...a cannabis play ????
Kiwi

Well I finally have one that is killing me more than AMRN.  IIPR.  Man

They may not know that the generic only covers high trigs but the doctor should include "DAW" meaning the script must be filled with brand Vascepa, dispense as written.

DJIA up 1300 , AMRN not so much , lol. Wait I know , it's another BUYING OPPORTUNITY. There, now we can all be friends !

Kube, Check the prescription.
Sleven,

Not sure if this has been discussed or mentioned but in the press release for the Investor Conference there was this line:
"Throughout the event, there will be no live interaction with audience participants". Fine. However, in the earnings call, Berg said the following (my question is about the part that I highlighted in bold as to what that is referring to. Will we have a live discussion with prescribers and partners?):

Commenting on the Company and its third quarter results, Aaron Berg, Amarin's President and CEO stated, "While we and our global partners continue to execute on our multipronged global strategy focused on getting VASCEPA/VAZKEPA into the hands of as many patients as possible, the senior leadership team and I, as well as the Board of Directors, remain committed to evaluating all opportunities to maximize the value and impact of this highly impactful product. To that end, we look forward to highlighting the global opportunity for VASCEPA/VAZKEPA and to hear directly from both prescribers and select partners from around the world on the impact of VASCEPA/VAZKEPA during our upcoming virtual Analyst and Investor Day on November 14./quote]

High triglycerides. Would the pharmacy know this?

Ram, wow, that's interesting. I did not catch that. I looked in the proxy, and it states 5 years. Maybe there is some sort of extension period.

Either way, let's hope we aren't still sitting here discussing this in 5 years. 😖

I see Trump win as a net positive for M&A and anticipate Biotech M&A to move forward with the headwind of uncertainty and the Biden admin removed.

Ram, JRoon, thanks for the responses. Even though when I first bought into Amarin (pre-Marine) I didn't think I would be holding more than 10 years later, I am somehow guessing we won't see a share BB ten years from now. Now, that could easily be because I will be dead by then!

Actually it's 10 years............from the call transcript

Pete Fishman -- Vice President and Global Controller

Sure. So, in terms of the repurchase, as you know, we did get approval to initiate a repurchase program. We have that ability to initiate it for 10 years. And similar to what we said last quarter, we're continuing to monitor the business and market dynamics to determine whether we will commence that program.

RMB, 5 years

It is the generic for Vascepa that is intended for high trigs, 500 or higher. It is NOT a generic for any other Vascepa indications.

How long is that share buyback approval for?

Kube, What indication is your prescription for?
Sleven,

RMB, I would not be fearful of a RS. While I don't know that it's the best course to take, and I don't necessarily trust Denner on everything, I do trust that when it comes to capital allocation decisions like this, they really do know what is best. They are far more experienced in capital markets than are any of us.

So my guess is that if it DOES end up happening, it's because of a strategic decision, not really a hail-mary, as it often can be with companies that do this. I would suspect they could get a two-fer on this if they went this direction - get the stock over the $1 mark and not need to worry about it, and if shorts do swoop in and push it back down, they could buy back more shares for the same $$.

Imagine a RS, Amarin buys back $50M, AND Sarissa buys some more. Maybe wishful thinking, but I could see a scenario where that happens.

Here's the other thing, along the same thinking - Sarissa may be trying to time some purchases to occur not long before they want to really push to get the company sold. So a combination of good news, share re-purchase, and some Sarissa buys would create massive price momentum. But they can't do it TOO soon, as they need to have the timing correct. A RS could help get them over the $1 price target without having to yet initiate the stock buyback.

Again, wild speculation here. But one thing is for certain - Amarin/Sarissa seem to have been very intentional about NOT marketing the company very much that past 18 months. Shit, CaptBeer has produced more (free) positive marketing than all of Amarin. Do you think they are just THAT bad at running businesses? I don't think so. I think price suppression has been very intentional.

Nah, that's just them talking. Really, what they are saying is "the generic substitute for Vascepa", which is valid.

Me either. Hopefully their objective is to make the case for why Amarin is investable. 

Just picked up icosapent ethyl (Hickma) refill. Person behind the counter referred to it as generic Vascepa,

Question…

Is the pharmacy infringing on Amarin’s IP by referring to Hickma icosapent ethyl as generic Vascepa?

ORBAPU, I don't ever recall one.
Sleven,

Anyone recall when Amarin last hosted an Analyst/Investor Day?

Not if they do at least a $25m stock buyback AND get a good reimbursement deal with Italy
Co has a market cap of only $257 m despite having $300m in cash and probably close to $200m ( haven't checked actual figures ) in regular and long term inventory .
So $500 m in cash and inventory ...but market says AMRN is worth $257m ???
I'm currently out of the stock ....just don't think RS is inevitable if they do a buyback and get a deal with Italy
JMO

Kiwi

I disagree but we shall see.

Reverse Split is all but certain...

It would be nice. Deathly afraid of RS so anything that can get us up.

I'll feel a little more confident in this little mini-push if we can get above the $0.65-0.67 range.

Filled: Good entry point on a two year hold investment.

Very good analogy..

Anyone still here? North will probably ride it to the end...

https://www.bioworld.com/articles/714134-australia-reimburses-vazkepa-a-decade-after-us-approval?v=preview
Sleven,

Ram; Congrats, just watched the highlights, how sweet it is, an OT win! Rams are looking good. NFC West is a tough Division. 

The Cardinals Defense again, plus Murray is finding his rhythm. I didn't get the final score of the Rams vs Seahawks? 

"Amarin is the Blackberry of drug companies." Not such a bad fate for Amarin, maybe. I've been following Blackberry for years, and its software that is still among the best for security-- military use, renewal of tank and other military vehicle contracts. I think that software finds uses in our 2020 Audi-S4, and its phone system. Sensors front and rear provide effortless parking in available spaces. With retirement of its CEO near, people on that message board believe a buyout is ready to occur. They posit a price target of ~ $10/share for Blackberry. PLTR, BAH have competition.


I saw the 60' episode, and learned something new about NVO in Denmark There is a holding company for NVO that holds ~ 76% of authorized NVO shares. The holding company is said to be larger than that of Bill Gates. Would that holding company miss some of those shares if they were used in a M/A of Amarin, the idea being to protect those millionaire, rather chubby, obese pickleball players, seen exercising on the 60 Minutes episode, from risk of death from CVD, stroke, AD, angina, etc.? Some of those NVO shares could also be used to buyout Avid Bioservices(CDMO) to provide extant facilities to make the Wegovy and Ozempic products of NVO in the U.S.

Chromo ....OT but since you were involved with CKD drugs ...thought you might be interested in this


Kiwi

60 Minutes had a piece on Novo Nordisk/Ozempic/Wegovy last night. Sometimes I think Amarin is the Blackberry of drug companies. Great product, but got left behind. 

Bought more today. I am almost 50% to my goal now.

This is over 5 years old!!!! Lol I think it came out right after approval.

This person should at least have the decency to put a $4 price target on the "rumor" so that for a few moments we all could actually dare to dream.

Nice dream - though 🙂

It's probably 5 years old

Do you have a link for this or is it fan-fic?

Big Pharma Eyes Amarin Pharmaceuticals for $25 Buyout Amid Strong Vascepa Potential

Amarin Pharmaceuticals, the company behind the cardiovascular treatment Vascepa, has recently become the focus of acquisition interest from several major pharmaceutical companies, with rumored offers around $25 per share. This speculation has gained traction as the company makes strides in expanding the reach of Vascepa, its omega-3-based treatment aimed at lowering cardiovascular risk, especially in Europe where market opportunities continue to grow.

Amarin’s Attractiveness as an Acquisition Target

Vascepa has carved a niche in the cardiovascular market by offering an effective alternative to standard treatments, supported by clinical trials demonstrating significant reductions in cardiovascular events. With recently issued patents extending its market exclusivity, Vascepa has solidified Amarin’s value proposition in a competitive landscape. This unique positioning, combined with Amarin’s cost-cutting measures and share repurchase programs, makes it a more appealing target for larger companies looking to broaden their cardiovascular portfolios.

Interested Buyers

Among the potential acquirers, industry giants like AstraZeneca, Pfizer, and Merck have been mentioned. These companies have historically shown interest in cardiovascular treatments, and Vascepa’s performance aligns well with their strategic goals of targeting lifestyle-related chronic diseases. Additionally, Amarin’s recent cost-saving measures and patents may enhance its valuation, making a $25 per share buyout feasible and attractive for shareholders.

Strategic Fit and Market Potential

For companies like AstraZeneca and Pfizer, adding Vascepa to their portfolios could provide a competitive edge in addressing cardiovascular health, a critical area of growth within their pipelines. With an estimated value above Amarin’s current market price, a $25 per share offer would represent a premium that may persuade shareholders to sell, especially as Amarin seeks to maintain its financial momentum and reduce operational costs.

While no official statements confirm an imminent buyout, the ongoing interest and strategic fit suggest that a significant acquisition could be on the horizon, promising both financial upside for Amarin’s investors and an expanded future for Vascepa under larger, resource-rich pharma companies.

Congrats Nukem on another Cardinals win.......

Marine-Derived Bioactive Ingredients in Functional Foods for Aging: Nutritional and Therapeutic Perspectives
Published: 4 November 2024
https://www.mdpi.com/1660-3397/22/11/496

Tat, Thanks. That is very useful information.
Sleven,

Rose…..he pays a little premium now to get all the stock…..a year from now, when the new formulation is announced and Amarin takes back U.S. market, he sells to big pharma for $10/share.